Dr Reddy’s Laboratories launches Paricalcitol injection in the US Market

zemplarDr. Reddy’s Laboratories Ltd said it launched Paricalcitol Injection, a therapeutic equivalent generic version of Zemplar injection in the United States market approved by the US Food & Drug Administration (USFDA).

The Zemplar brand and generic had US sales of approximately $22.5 million for the most recent twelve months ending in July 2016 according to IMS Health.

Dr. Reddy’s Paricalcitol injection is available in 2 mog, 5mcg, and 10 mog, and is the first ANDA product launched in the US market.

Zemplar is a registered trademark of ABBVIE Inc.

Dr. Reddy’s Laboratories Ltd. is an India pharmaceutical company and offers products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.